Page 97 - GUIAS ESC ESH 2018

ESC/ESH Guidelines 97

.
576. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular dis- . . 595. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL,
ease: meta-analysis of prospective cohort studies. J Am Coll Cardiol . . Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L,
2011;58:1378–1385. . . . Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-
577. La Torre A, Giupponi G, Duffy D, Conca A, Catanzariti D. Sexual dysfunction . . Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel.
related to drugs: a critical review. Part IV: cardiovascular drugs. . . Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in
Pharmacopsychiatry 2015;48:1–6. . . . patients at high risk of cardiovascular disease: evidence and guidance for man-
578. Pickering TG, Shepherd AM, Puddey I, Glasser DB, Orazem J, Sherman N, . . agement. Eur Heart J 2011;32:1345–1361.
Mancia G. Sildenafil citrate for erectile dysfunction in men receiving multiple . . 596. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R,
antihypertensive agents: a randomized controlled trial. Am J Hypertens . . Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E,
2004;17:1135–1142. . . . Ostergren J, ASCOT Investigators. Prevention of coronary and stroke events
579. Foy CG, Newman JC, Berlowitz DR, Russell LP, Kimmel PL, Wadley VG, . . with atorvastatin in hypertensive patients who have average or lower-than-
Thomas HN, Lerner AJ, Riley WT. Blood pressure, sexual activity, and dysfunc- . . average cholesterol concentrations, in the Anglo-Scandinavian Cardiac
tion in women with hypertension: baseline findings from the Systolic Blood . . . Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised
Pressure Intervention Trial (SPRINT). J Sex Med 2016;13:1333–1346. . . controlled trial. Lancet 2003;361:1149–1158.
580. Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on . . 597. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig
angiogenesis blockade. Curr Hypertens Rep 2007;9:320–328. . . W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J,
581. Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A, Mouhayar E. . . . Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular
Hypertension induced by chemotherapeutic and immunosuppresive agents: a . . events in men and women with elevated C-reactive protein. N Engl J Med
new challenge. Crit Rev Oncol Hematol 2015;93:28–35. . . 2008;359:2195–2207.
582. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, . . 598. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P,
Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH. Initial assess- . . . Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M,
ment, surveillance, and management of blood pressure in patients receiving vas- . . Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K,
cular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst . . Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H,
2010;102:596–604. . . Gao P, Diaz R, Lonn E, HOPE-3 Investigators. Cholesterol lowering in
583. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular . . . intermediate-risk persons without cardiovascular disease. N Engl J Med
complications of cancer therapy: best practices in diagnosis, prevention, and . . 2016;374:2021–2031.
management: Part 2. J Am Coll Cardiol 2017;70:2552–2565. . . 599. Authors/Task Force Members: Catapano AL, Graham I, De Backer G, Wiklund
584. Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F. Arterial hypertension . . . O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen
and cancer. Int J Cancer 2014;134:2269–2277. . . TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM,
585. Aronson S, Mythen MG. Perioperative management of high-risk patients: going . . Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the
beyond "avoid hypoxia and hypotension". JAMA 2017;318:1330–1332. . . Management of Dyslipidaemias. Eur Heart J 2016;37:2999–3058.
586. Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, Ford I, . . . 600. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR,
Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, . . LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D,
Kjeldsen KP, Longrois D, Luscher TF, Pierard L, Pocock S, Price S, Roffi M, . . Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM
Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C. 2014 ESC/ESA . . . Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipopro-
Guidelines on non-cardiac surgery: cardiovascular assessment and management: . . teins and the risk for cardiovascular events: a meta-analysis of statin trials. JAm
The Joint Task Force on non-cardiac surgery: cardiovascular assessment and . . Coll Cardiol 2014;64:485–494.
management of the European Society of Cardiology (ESC) and the European . . 601. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de
Society of Anaesthesiology (ESA). Eur Heart J 2014;35:2383–2431. . . . Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW.
587. Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P, Bertran S, Leone . . The benefits of statins in people without established cardiovascular disease but
M, Pastene B, Piriou V, Molliex S, Albanese J, Julia JM, Tavernier B, Imhoff E, . . with cardiovascular risk factors: meta-analysis of randomised controlled trials.
Bazin JE, Constantin JM, Pereira B, Jaber S. Effect of individualized vs standard . . . BMJ 2009;338:b2376.
blood pressure management strategies on postoperative organ dysfunction . . 602. Cholesterol Treatment Trialists’ Collaboration, Fulcher J, O’Connell R, Voysey
among high-risk patients undergoing major surgery: a randomized clinical trial. . . M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun
JAMA 2017;318:1346–1357. . . H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi
588. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure . . . MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among
randomised controlled trials of beta-blockade to prevent perioperative death in . . men and women: meta-analysis of individual data from 174,000 participants in
non-cardiac surgery. Heart 2014;100:456–464. . . 27 randomised trials. Lancet 2015;385:1397–1405.
589. Blessberger H, Kammler J, Domanovits H, Schlager O, Wildner B, Azar D, . . 603. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens
Schillinger M, Wiesbauer F, Steinwender C. Perioperative beta-blockers for pre- . . . 2000;14:687–690.
venting surgery-related mortality and morbidity. Cochrane Database Syst Rev . . 604. Lip GY, Felmeden DC, Dwivedi G. Antiplatelet agents and anticoagulants for
2018;3:CD004476. . . hypertension. Cochrane Database Syst Rev 2011;12:CD003186.
590. Zou Z, Yuan HB, Yang B, Xu F, Chen XY, Liu GJ, Shi XY. Perioperative . . 605. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for
angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor . . . ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the
blockers for preventing mortality and morbidity in adults. Cochrane Database . . Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510.
Syst Rev 2016;1:CD009210. . . 606. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M,
591. Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Cote EP, Guyatt . . . Marin F, Palareti G, Kirchhof P. Bleeding risk assessment and management in
GH,Sessler DI,Le Manach Y,BorgesFK, Tandon V, WorsterA, Thompson A, . . atrial fibrillation patients. Executive Summary of a Position Document from the
Koshy M, Devereaux B, Spencer FA, Sanders RD, Sloan EN, Morley EE, Paul J, . . European Heart Rhythm Association [EHRA], endorsed by the European
Raymer KE, Punthakee Z, Devereaux PJ. Withholding versus continuing angiotensin- . . Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost
converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac . . . 2011;106:997–1011.
surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort . . 607. Lip GY, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on
evaluatioN Prospective Cohort. Anesthesiology 2017;126:16–27. . . the use and misuse of bleeding risk scores. J Thromb Haemost
592. London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative . . . 2016;14:1711–1714.
beta-blockade with mortality and cardiovascular morbidity following major non- . . 608. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA,
cardiac surgery. JAMA 2013;309:1704–1713. . . Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman
593. Andersson C, Merie C, Jorgensen M, Gislason GH, Torp-Pedersen C, . . B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial
Overgaard C, Kober L, Jensen PF, Hlatky MA. Association of beta-blocker ther- . . . Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N
apy with risks of adverse cardiovascular events and deaths in patients with . . Engl J Med 2016;375:311–322.
ischemic heart disease undergoing noncardiac surgery: a Danish nationwide . . 609. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I,
cohort study. JAMA Intern Med 2014;174:336–344. . . Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson
594. Kwon S, Thompson R, Florence M, Maier R, McIntyre L, Rogers T, Farrohki E, . . . J, Vilsboll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular out-
Whiteford M, Flum DR. Beta-blocker continuation after noncardiac surgery: a . . comes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844.
report from the surgical care and outcomes assessment program. Arch Surg . . 610. Birtwhistle RV, Godwin MS, Delva MD, Casson RI, Lam M, MacDonald SE,
2012;147:467–473. . . . . Seguin R, Ruhland L. Randomised equivalence trial comparing three month and

Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy339/5079119
by guest
on 27 August 2018